



**ORYZON GENOMICS, S.A.**

Pursuant to the provisions of article 227 of the Restated Text of the Securities Market Act approved by Royal Legislative Decree 4/2015 of 23 October, ORYZON GENOMICS, S.A. ("**ORYZON**" or the "**Company**") hereby gives notice of the following

### **OTHER RELEVANT INFORMATION**

ORYZON announces the incorporation of a new Independent Director to its Board of Directors.

This information is summarized in the attached pressrelease that will be distributed today.

Madrid, 17 April 2020

## ORYZON appoints Eisai executive Vanessa Almendro Navarro to Board of Directors

- ❖ **Dr. Vanessa Almendro Navarro, PhD, MBA, is Director of Strategy and Operations at EISAI's Genetic Guided Discovery in Dementia (G2D2) Center in Boston**

**MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, April 17th, 2020** - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with high unmet medical need, is pleased to announce the appointment of Dr. Vanessa Almendro Navarro, of Eisai US, as an independent director. Dra. Almendro will be Lead Director and member of the Remuneration and Nomination Committee.

Carlos Buesa, CEO of Oryzon, said: "We welcome Vanessa to our board. As an oncologist with extensive experience in drug development, she is a recognized expert in the US biotech industry. We very much look forward to her guidance and support as we execute on our objectives in the coming years."

Dr. Almendro has extensive experience in corporate strategy, and in the clinical and commercial development of therapeutics in a number of disease areas, including oncology, neurology, diabetes and pain. Over the past 16 years, she has been active across basic research, target discovery, drug development, clinical strategy, new product planning, strategic alliances, and business development. Following conferral of her PhD, she held a postdoctoral appointment as Group Leader in the Department of Oncology Medicine at the Hospital Clinico-IDIBAPS in Barcelona. From 2008-2014 she was a Visiting Scientist at the Dana-Farber Cancer Institute in Boston. Her career in the pharmaceutical industry began at Vertex Pharmaceuticals where she served as Head of Experimental Biology and then as Associate Director, Global Marketing Pipeline and Strategic Management. Subsequently, Dr. Almendro joined Cogen Therapeutics as Director of Strategy and Operations, until her current position as Director of Strategy and Operations at the Genetic Guided Discovery in Dementia (G2D2) Center of Eisai in Cambridge, MA. Eisai is one of the largest Japanese pharmaceutical companies and has a global footprint.

Dr. Almendro combines her current functions with the position of Interim Managing Director at the philanthropic investment fund of the National Brain Tumor Society (NBTS), a charitable organization devoted to supporting research and promotion of therapies for the treatment of brain tumors. She also works with the Massachusetts Biotechnology Council as a mentor to start-ups and biotech companies.

Dr. Almendro said: "I am excited to join the Oryzon Board at this important time for the company. Epigenome remodeling with LSD1 inhibitors has great therapeutic potential for the treatment of multiple diseases, and Oryzon is uniquely positioned to explore and advance the clinical development of these

inhibitors. I am eager to start working with the rest of the Board and the company to advance the development of these epigenetic candidates in the hope of helping patients with devastating diseases.”

Following the appointment, Oryzon’s Board of Directors is composed of seven Directors, of which four are independent, one "other," and two Executive Directors. Three of the Directors have a biomedical background, while the others have experience in finance, auditing and marketing. Three of the Directors are women.

### **About Oryzon**

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has offices in Spain and the United States. For more information, visit [www.oryzon.com](http://www.oryzon.com)

### **FORWARD-LOOKING STATEMENTS**

This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon’s securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

**IR & Media, US & Europe:**  
**LifeSci Advisors LLC**  
**Hans Herklots**  
+41 79 598 7149  
[hherklots@lifesciadvisors.com](mailto:hherklots@lifesciadvisors.com)

**Spain:**  
**ATREVIA**  
**Patricia Cobo/Carlos C. Ungría**  
+34 91 564 07 25  
[pcobo@atrevia.com](mailto:pcobo@atrevia.com)  
[cungria@atrevia.com](mailto:cungria@atrevia.com)

**Oryzon:**  
**Emili Torrell**  
**BD Director**  
+34 93 515 13 13  
[etorrell@oryzon.com](mailto:etorrell@oryzon.com)